Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)

被引:16
作者
Azuma, A
Huang, P
Matsuda, A
Plunkett, W
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan
关键词
nucleoside analog; CNDAC; DNA synthesis; DNA polymerase;
D O I
10.1016/S0006-2952(01)00617-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and pharmacodynamics of the novel clinical candidate 2'-C-cyano-2'-deoxy-1-beta -D-arabino-pentofuranosylcytosine (CNDAC) were investigated in human lymphoblastoid CCRF-CEM cells and human myeloblastic leukemia ML-1 cells. Formation of CNDAC 5'-mono-, di-, and triphosphate (CNDACTP) was concentration-dependent; nucleotide accumulation was greater in the lymphoid cells than in the myeloid cells. The nucleotides were eliminated with linear kinetics from both lines, but were retained more effectively by the ML-1 cells. DNA synthesis was selectively inhibited by a 4-hr treatment with CNDAC in CCRF-CEM and ML-1 cells; the Ic,, values were 1 and 0.8 muM, respectively. Evaluation of the polymerization reaction of a primer on an M13mp19(+) template by human DNA polymerase alpha indicated that CNDACTP was incorporated effectively (K-m = 0.22 muM) opposite a complementary dGMP in the template strand. CNDACTP competed with the normal substrate, dCTP, for incorporation, and the two nucleotides showed similar substrate efficiencies (V-max/K-m: dCTP = 0.91; CNDACTP = 0.77). Primer extension was potently inhibited by CNDAC triphosphate (Ki = 23 nM); once the analog had been incorporated, further extension was not observed in vitro, suggesting that primers containing a 3'-terninal nucleotide analog were high K, substrates for polymerase cu. Thus, the ability of human leukemia cells to effectively accumulate and retain CNDACTP, coupled with the favorable kinetics of competition for incorporation into DNA, and the relatively strong ability of the analog to terminate further extension, are likely to contribute to the cytotoxic action of CNDAC. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1497 / 1507
页数:11
相关论文
共 43 条
[1]   NUCLEOSIDES AND NUCLEOTIDES .122. 2'-C-CYANO-2'-DEOXY-1-BETA-D-ARABINOFURANOSYLCYTOSINE AND ITS DERIVATIVES - A NEW CLASS OF NUCLEOSIDE WITH A BROAD ANTITUMOR SPECTRUM [J].
AZUMA, A ;
NAKAJIMA, Y ;
NISHIZONO, N ;
MINAKAWA, N ;
SUZUKI, M ;
HANAOKA, K ;
KOBAYASHI, T ;
TANAKA, M ;
SASAKI, T ;
MATSUDA, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (26) :4183-4189
[2]   2'-DEOXY-2'-METHYLENECYTIDINE AND 2'-DEOXY-2',2'-DIFLUOROCYTIDINE 5'-DIPHOSPHATES - POTENT MECHANISM-BASED INHIBITORS OF RIBONUCLEOTIDE REDUCTASE [J].
BAKER, CH ;
BANZON, J ;
BOLLINGER, JM ;
STUBBE, J ;
SAMANO, V ;
ROBINS, MJ ;
LIPPERT, B ;
JARVI, E ;
RESVICK, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) :1879-1884
[3]  
BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689
[4]  
CARMICHAEL J, 1987, CANCER RES, V47, P943
[5]   Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [J].
Cassileth, PA ;
Harrington, DP ;
Appelbaum, FR ;
Lazarus, HM ;
Rowe, JM ;
Paietta, E ;
Willman, C ;
Hurd, DD ;
Bennett, JM ;
Blume, KG ;
Head, DR ;
Wiernik, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1649-1656
[6]  
CHOU TC, 1977, CANCER RES, V37, P3561
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]  
DONEHOWER RC, 2000, P AN M AM SOC CLIN, V19, pA196
[9]  
FURTH JJ, 1968, CANCER RES, V28, P2061
[10]  
GANDHI V, 1990, CANCER RES, V50, P3675